Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-1080. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 1.00 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1080 SCHEMBL30298327 | 1.00 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL394519 | 1.00 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL29361806 | 1.00 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL3701569 | 1.00 | CDK7 (1.00) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL395245 | 0.99 | CDK7 (0.98) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2684436 | 0.95 | CDK7 (0.91) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL27755135 | 0.95 | CDK7 (0.91) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2685061 | 0.94 | CDK7 (0.88) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2686165 | 0.93 | CDK7 (0.86) | CDK7CDK1CDK2DYRK3GSK3B | |
| Azd-1080 SCHEMBL2685875 | 0.93 | CDK7 (0.86) | CDK7CDK1CDK2DYRK3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235998-A1 | PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNE MODULATORY ACTIVITY | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| CN-119410582-A | Culture medium and culture method of stem cell-like memory T lymphocytes | 赛德特生物制药有限公司 | 2025-02-11 | — | — | CN | claimed |
| WO-2025235998-A1 | PLURIPOTENT STEM CELL DERIVED MESENCHYMAL STEM CELLS WITH ENHANCED IMMUNE MODULATORY ACTIVITY | IMMORTA BIO, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4627061-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119410582-B | Culture medium and culture method of stem cell-like memory T lymphocytes | 赛德特生物制药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119410582-A | Culture medium and culture method of stem cell-like memory T lymphocytes | 赛德特生物制药有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114945378-B | Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells and related uses thereof | 休斯敦大学体系 | 2024-11-19 | — | — | CN | disclosed |
| WO-2024113351-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| EP-4171605-A1 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115768869-A | Methods of generating vascular smooth muscle cells derived from pluripotent stem cells, uses thereof, and compositions related thereto | 埃默里大学 | 2023-03-07 | — | — | CN | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | Frequency Therapeutics, Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220096639-A1 | THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | Frequency Therapeutics, Inc. | 2022-03-31 | — | — | US | disclosed |
| CN-114174496-A | Compositions and methods for generating hair cells by inhibiting epigenetic targets | 频率医疗公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | GSK3B 1064/4885CDK7 442/4885CDK1 3061/4885 |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | GSK3B 92/4885CDK7 389/4885CDK1 607/4885 |
| US-20220096639-A1 | THERMOREVERSIBLE COMPOSITIONS FOR ADMINISTRATION OF THERAPEUTIC AGENTS | MKI67, MCL1, HSPE1 | GSK3B 575/4885CDK7 897/4885CDK1 341/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | GSK3B 678/4885CDK7 794/4885CDK1 2007/4885 |
| US-20220133740-A1 | VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT3A, WNT1, WNT3 | GSK3B 42/4885CDK7 902/4885CDK1 3063/4885 |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA2 | GSK3B 1128/4885CDK7 174/4885CDK1 2998/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | GSK3B 63/4885CDK7 615/4885CDK1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.